Application of sintilimab combined with XELOX regimen to patients with colorectal cancer
Objective To investigate the effect of sintilimab combined with XELOX regimen(oxaliplatin plus capecitabine)in colorectal cancer patients.Methods The medical records of 100 colorectal cancer patients admitted from June 2021 to March 2023 were retrospectively collected.According to the different treatment methods,50 patients who received XELOX regimen were included in the control group,50 patients who received sintilimab combined with XELOX regimen were included in the observation group.The treatment effect,tumor markers(cancer antigen CA19-9[CA-199],carcinoembryonic antigen[CEA]),T-cell subsets(CD3+,CD4+,CD8+,CD4+/CD8+)and drug side effects(thyroid dysfunction,anemia,rash,bone marrow suppression,nausea and vomiting,liver function damage)during chemotherapy were compared between the two groups before treatment and after 4 cycles of chemotherapy,thus exploring the application effect of sintilimab combined with XELOX on colorectal cancer patients.Results The objective response rate of the observation group was significantly higher than that of the control group(P＜0.05).After treatment,CA-199 and CEA levels in both groups decreased,which were significantly lower in the observation group than those of the control group(P＜0.05).After treatment,CD3+,CD4+,and CD4+/CD8+ levels in the observation group were significantly higher than before treatment,and which were significantly higher than those of the control group(P＜0.05).CD3+,CD4+,CD8+,and CD4+/CD8+ levels after treatment in the control group were comparable to those before treatment(P＞0.05).The number of cases of abnormal thyroid function and anemia in the observation group was significantly greater than that in the control group(P＜0.05).Conclusion Sintilimab combined with XELOX regimen can reduce the levels of tumor markers in colorectal cancer patients,improve immune function,and has a definite efficacy and controllable side effects.
colorectal cancersintilimabXELOX regimen(oxaliplatin plus capecitabine)
NETL
NSTL
万方数据
维普
